Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | RXRB | P28702 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228292 | 0.98 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL7665986 | 0.92 | MCL1 (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Formaldehyde SCHEMBL27728539 | 0.92 | RXRA (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8616107 | 0.92 | MCL1 (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL12717358 | 0.92 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Methyl Alcohol SCHEMBL27428217 | 0.92 | LMNA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL11839266 | 0.90 | APP (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL419232 | 0.89 | MAOB (0.69) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL13903288 | 0.89 | MAOB (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Formic Acid SCHEMBL28571007 | 0.87 | RXRA (0.61) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110066302-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-3743412-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-10597361-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2019144864-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-08-01 | — | — | WO | disclosed |
| CN-104803846-B | The method for preparing bis- [4- (6- acryloyl-oxy hexyl) phenyl] hexamethylene -1,4- dicarboxylic esters | 默克专利股份有限公司 | 2019-06-11 | — | — | CN | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| CN-104803846-A | Method for the preparation of bis[4-(6-acryloyloxy-hexyl)-phenyl]cyclohexane-1,4-dicarboxylate | MERCK PATENT GMBH | 2015-07-29 | — | — | CN | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2483251-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| EP-1727785-A1 | PHENYL INDAN DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087708-A1 | PHENYL INDAN DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
| US-5254577-A | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5130316-A | Arylbenzene oxazolidinone compounds | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-14 | — | — | US | disclosed |
| US-5043443-A | Bactericides | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-4948801-A | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| US-4011321-A | 6-(3-SUBSTITUTED AMINO-2-HYDROXYPROPOXYARYL)-4,5-DIHYDRO-3(2H)-PYRIDAZINONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597361-B2 | Ethynylbenzene derivatives | Q6ZSR9, EPX, ZYX | LMNA 2493/4885CYP1A2 886/4885PTGS1 2547/4885 |
| US-20170349544-A1 | Ethynylbenzene Derivatives | Q6ZSR9, EPX, ZYX | LMNA 2493/4885CYP1A2 886/4885PTGS1 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.